Irradiation and postangioplasty restenosis - A recent overview

被引:7
|
作者
Ishiwata, S [1 ]
Robinson, K [1 ]
Chronos, N [1 ]
Crocker, IR [1 ]
King, SB [1 ]
机构
[1] Toranomon Hosp, Ctr Cardiovasc, Minato Ku, Tokyo 1058470, Japan
来源
JAPANESE HEART JOURNAL | 2000年 / 41卷 / 05期
关键词
brachytherapy; restenosis; review;
D O I
10.1536/jhj.41.541
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
One of the most intriguing developments in recent years towards prevention of restenosis after angioplasty is the use of ionizing radiation. The background for the use of radiation treatment for this application is sound, since radiation is used not only to treat malignant cancerous growths but also is used for treatment of benign hyperplastic disorders such as post-surgical keloid fort-nation and recurrence of pterygium after surgical removal. Restenosis can be considered a form of overexuberant wound healing triggered by angioplasty. Ionizing radiation inhibits serum-stimulated proliferation of many cell types including fibroblasts and smooth muscle cells in vitro and also suppresses the synthesis of collagen by cultured fibroblasts. Liermann who showed inhibition of post-stent restenosis first used ionizing radiation for restenosis prevention clinically in iliac and iliofemoral arteries. Subsequently, extensive animal studies in various restenosis models have shown a profuund inhibitory effect or catheter-based radiation (endovascular brachytherapy) on neointima formation and overall vessel shrinkage (negative remodeling). Based on these results clinical trials have been initiated with several types of devices and isotopes. Among these are Ir-192, P-32, Y-90, Sr-90/Y and Re-188. Additionally, radioactive stents have been developed; devices for clinical use are made radioactive at the mu Ci level by surface implantation of 32P ions. Results from early clinical trials are encouraging and brachytherapy appears safe for clinical use and at an appropriate dose, may be highly effective for restenosis prevention.
引用
收藏
页码:541 / 570
页数:30
相关论文
共 50 条
  • [31] Perivascular responses after angioplasty which may contribute to postangioplasty restenosis - A role for circulating myofibroblast precursors?
    Wilcox, JN
    Okamoto, E
    Nakahara, K
    Vinten-Johansen, J
    ATHEROSCLEROSIS VI, 2001, 947 : 68 - 92
  • [32] ANTIPROLIFERATIVE AND FIBROSUPPRESSIVE EFFECTS OF CERTAIN HYDROXYLASE INHIBITORS IN HUMAN CORONARY ATHEROSCLEROTIC CELLS - IMPLICATIONS FOR POSTANGIOPLASTY RESTENOSIS
    MCCAFFREY, T
    POMERANTZ, K
    DU, B
    FALCONE, D
    SANBORN, T
    SPOKOJNY, A
    HANAUSKEABEL, H
    FASEB JOURNAL, 1994, 8 (04): : A538 - A538
  • [33] REGULATION OF SMOOTH-MUSCLE CELL-PROLIFERATION AND ITS POSSIBLE ROLE IN PREVENTING RESTENOSIS POSTANGIOPLASTY
    NIKOL, S
    HOFLING, B
    WIENER KLINISCHE WOCHENSCHRIFT, 1995, 107 (13) : 379 - 389
  • [34] A human arterial organ culture model of postangioplasty restenosis:: results up to 56 days after ballooning
    Voisard, R
    von Eicken, J
    Baur, R
    Gschwend, JE
    Wenderoth, U
    Kleinschmidt, K
    Hombach, V
    Höher, M
    ATHEROSCLEROSIS, 1999, 144 (01) : 123 - 134
  • [35] Adenoviral transfer of endothelial nitric oxide synthase attenuates lesion formation in a novel murine model of postangioplasty restenosis
    von der Thüsen, JH
    Fekkes, ML
    Passier, R
    van Zonneveld, AJ
    Mainfroid, V
    van Berkel, TJC
    Biessen, EAL
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (02) : 357 - 362
  • [36] Gene therapy of vascular disorders. Use of gax gene transfer as a molecular strategy to prevent postangioplasty restenosis
    Le Roux, A
    Maillard, L
    Conard, V
    Ratet, N
    Perlman, H
    Mahfoudi, A
    Isner, JM
    Walsh, K
    Branellec, D
    ATHEROSCLEROSIS XI, 1998, 1155 : 673 - 683
  • [37] RESTENOSIS AFTER CORONARY ANGIOPLASTY - AN OVERVIEW
    CALIFF, RM
    FORTIN, DF
    FRID, DJ
    HARLAN, WR
    OHMAN, EM
    BENGTSON, JR
    NELSON, CL
    TCHENG, JE
    MARK, DB
    STACK, RS
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 17 (06) : B2 - B13
  • [38] RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR (RHM-CSF) DOES NOT ENHANCE POSTANGIOPLASTY RESTENOSIS
    MASON, L
    KEANEY, J
    VITA, J
    HAYES, L
    FERRANTI, T
    CLINTON, S
    LOSCALZO, J
    SCHAUB, R
    FASEB JOURNAL, 1994, 8 (04): : A318 - A318
  • [39] Comparison of myocardial perfusion reserve before and after coronary balloon predilatation and after stent implantation in patients with postangioplasty restenosis
    Haude, M
    Caspari, G
    Baumgart, D
    Brennecke, R
    Meyer, J
    Erbel, R
    CIRCULATION, 1996, 94 (03) : 286 - 297
  • [40] Percutaneous overexpression of tissue factor pathway inhibitor interferes with postangioplasty restenosis by coagulation-dependent and -independent mechanisms.
    Kopp, CW
    Hölzenbein, T
    Steiner, S
    Marculescu, R
    Bergmeister, H
    Seidinger, D
    Mosberger, I
    Kaun, C
    Cejna, M
    Brostjan, C
    Horvath, R
    Maurer, G
    Binder, BR
    de Martin, R
    Minar, E
    AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (6A): : 114H - 115H